Literature DB >> 6135618

Neuroleptic inhibition of 6,7-ADTN-induced hyperactivity after injection into the nucleus accumbens. Specificity and comparison with other models.

J Arnt.   

Abstract

The dopamine agonist 6,7-ADTN induced locomotor stimulation after injection into the nucleus accumbens of rats. This hyperactivity was stereospecifically antagonized by peripheral injection of typical and atypical neuroleptics, except sulpiride, regardless of structural class. The potency of 14 neuroleptics correlated significantly to that in other neuroleptic in vivo models in rats, i.e. cataleptogenic and amphetamine-antagonistic (stereotypy, circling) activity. Sulpiride was inactive after peripheral injection, whereas intraacumbens sulpiride antagonized 6,7-ADTN-induced hyperactivity with a higher potency than that found for locally injected cis-(Z)-flupentixol, haloperidol and clebopride. Blockade of alpha 1-adrenergic receptors by systemic prazosin or locally injected phentolamine also antagonized 6,7-ADTN, whereas antagonists of alpha 2-adrenergic, beta-adrenergic, muscarinic and serotoninergic receptors were without effect. Furthermore, the cis-(Z)-flupentixol and haloperidol-induced 6,7-ADTN blockade was only slightly or not reversed by additional antimuscarinic (scopolamine) or antiserotonergic (methysergide) treatment. It is concluded that antagonism of 6,7-ADTN-induced hyperactivity is a relevant model for detecting neuroleptic activity with minimal influence of anticholinergic and antiserotonergic activity, but that the dopamine receptor within the nucleus accumbens responsible for the locomotor stimulation is similar to that involved in other behavioural effects of neuroleptics. It is suggested that an apparent preferential limbic action of some neuroleptics (e.g. clozapine and chlorprothixene) is more likely to be explainable by their simultaneous blocking effect on dopaminergic, alpha-adrenergic and muscarinic receptors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135618     DOI: 10.1016/0014-2999(83)90212-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Dopamine D2 agonist-induced behavioural depression is reversed by dopamine D1 agonists.

Authors:  D M Jackson; S B Ross; S R Edwards
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

2.  Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics.

Authors:  J G Csernansky; C T Wrona; M E Bardgett; T S Early; J W Newcomer
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

3.  Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride.

Authors:  E S Prosser; R Pruthi; J G Csernansky
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  The nucleus accumbens and antidepressants: modulation of ergometrine-induced hyperactivity by typical and atypical antidepressants and neuroleptics in rats.

Authors:  A R Cools
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats.

Authors:  J Arnt; J Hyttel
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

6.  Sulpiride blocks postsynaptic dopamine receptors in the nucleus accumbens.

Authors:  R Morgenstern; H Fink
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

7.  The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs.

Authors:  B A Ellenbroek; B W Peeters; W M Honig; A R Cools
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.